These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Therapy of ED: PDE-5 Inhibitors.
    Author: Shabsigh R.
    Journal: Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092.
    Abstract:
    The development of phosphodiesterase inhibitors, which are selective for the type 5 isoenzyme, has revolutionized the initial evaluation and treatment of men with erectile dysfunction. These agents can be taken orally and are effective in 60-70% of patients with erectile dysfunction, and they have low incidences of side effects when taken as recommended. The major contraindications are concomitant use with nitrates or the alpha-blockers terazosin and doxazosin. The major difference in the three approved inhibitors is that tadalafil has a considerably longer serum half-life, which provides a longer window of opportunity and potentially side effects.
    [Abstract] [Full Text] [Related] [New Search]